troglitazone has been researched along with Cells, Neoplasm Circulating in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Noort, V | 1 |
| Schölch, S | 1 |
| Iskar, M | 1 |
| Zeller, G | 1 |
| Ostertag, K | 1 |
| Schweitzer, C | 1 |
| Werner, K | 1 |
| Weitz, J | 1 |
| Koch, M | 1 |
| Bork, P | 1 |
1 other study available for troglitazone and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling.
Topics: Animals; Antineoplastic Agents; Chromans; Citalopram; Colorectal Neoplasms; Gene Expression Profilin | 2014 |